Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Meropenem Trihydrate: Broad-Spectrum Carbapenem Antibioti...

    2026-01-24

    Meropenem Trihydrate: Broad-Spectrum Carbapenem Antibiotic for Gram-Negative and Gram-Positive Bacterial Research

    Executive Summary: Meropenem trihydrate is a broad-spectrum β-lactam antibiotic with low MIC90 values against clinically relevant Gram-negative and Gram-positive bacteria, including Escherichia coli and Klebsiella pneumoniae (APExBIO; Dixon et al., 2025). Its mechanism of action involves inhibition of bacterial cell wall synthesis via penicillin-binding protein interaction. The compound's efficacy is pH-dependent, with enhanced activity at physiological pH 7.5. Meropenem trihydrate is a gold-standard reference for resistance, infection, and metabolomics studies, but its clinical use is not indicated for research-grade material. Bench and workflow integration require precise solubility and storage control to maintain compound stability and reproducibility.

    Biological Rationale

    Carbapenem antibiotics, such as Meropenem trihydrate, are critical for research targeting multidrug-resistant bacterial pathogens. They are effective against both Gram-negative and Gram-positive organisms, including those producing extended-spectrum β-lactamases (ESBLs) (Dixon et al., 2025). The global rise of carbapenemase-producing Enterobacterales (CPE) increases the urgency for robust reference compounds in resistance profiling and infection model development. Meropenem trihydrate is especially valued for its low minimum inhibitory concentration (MIC90), enabling precise benchmarking of antibacterial susceptibility assays. Its spectrum covers Enterobacter spp., Citrobacter spp., Proteus mirabilis, Morganella morganii, Streptococcus pyogenes, and Streptococcus pneumoniae. This compound supports research into cell wall-targeting therapies and the molecular mechanisms underlying carbapenem resistance. For a deeper workflow perspective, see the guide on advanced Meropenem trihydrate protocols; this article extends those protocols by incorporating pH-dependence and metabolomics insights.

    Mechanism of Action of Meropenem trihydrate

    Meropenem trihydrate inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). This action impedes the final transpeptidation step in peptidoglycan synthesis, compromising cell wall integrity and leading to osmotic lysis and cell death (APExBIO). Its structure confers stability against many β-lactamases, including ESBLs, but it remains susceptible to hydrolysis by certain carbapenemases (notably KPC, NDM, and OXA-48 variants). The compound’s efficacy is influenced by environmental pH: at pH 7.5, MIC values are lower (i.e., activity is higher) compared to acidic conditions (pH 5.5), reinforcing the importance of physiological assay conditions.

    Evidence & Benchmarks

    • Meropenem trihydrate exhibits MIC90 values ≤0.12 μg/mL against Escherichia coli and Klebsiella pneumoniae at pH 7.5 in standardized broth microdilution assays (Dixon et al., 2025).
    • The antibiotic inhibits a wide range of gram-negative and gram-positive bacteria, including Enterobacter spp., Citrobacter spp., and Streptococcus pneumoniae (see APExBIO B1217 data).
    • Resistance to carbapenems in Enterobacterales is mainly due to enzyme-mediated hydrolysis by carbapenemases, with additional contributions from efflux and porin mutations (Dixon et al., 2025).
    • Metabolomics profiling differentiates carbapenem-resistant from susceptible strains by identifying distinct metabolic biomarkers after 6 hours of growth without antibiotics, providing a diagnostic avenue (Dixon et al., 2025).
    • Meropenem trihydrate solutions are stable for short-term use when stored at -20°C and dissolved in water (≥20.7 mg/mL with gentle warming) or DMSO (≥49.2 mg/mL), but are insoluble in ethanol (APExBIO).
    • In rodent models of acute necrotizing pancreatitis, Meropenem trihydrate reduces hemorrhage, fat necrosis, and pancreatic infection, with enhanced results when combined with deferoxamine (APExBIO B1217 application notes).

    For additional comparative benchmarks and troubleshooting, see this article which emphasizes Meropenem trihydrate's role as a gold-standard compound; the current review updates its coverage with recent metabolomics and resistance biomarker findings.

    Applications, Limits & Misconceptions

    Meropenem trihydrate is fundamental to research in antibiotic resistance, infection modeling, and bacterial metabolism. Its use spans:

    • Reference control in MIC and antibacterial susceptibility testing.
    • Metabolomics workflows for rapid resistance phenotyping (Dixon et al., 2025).
    • In vivo infection models, including acute necrotizing pancreatitis studies.

    Clinical diagnostic or therapeutic use is not authorized for research-grade Meropenem trihydrate. Its efficacy in the presence of highly active carbapenemases (e.g., NDM-1, KPC) is reduced due to rapid hydrolysis. For nuanced application guidance, this workflow guide details troubleshooting strategies, while the current article extends coverage to include metabolomic biomarker integration.

    Common Pitfalls or Misconceptions

    • Research-grade Meropenem trihydrate (such as APExBIO B1217) is not suitable for human or veterinary clinical use.
    • It does not inhibit all bacterial β-lactamases; carbapenemase-producing organisms may show resistance.
    • Stability is compromised at room temperature or in solution for prolonged periods; always store at -20°C and use fresh solutions.
    • Solubility in organic solvents like ethanol is poor; use water or DMSO as directed.
    • Interpret MIC data in context: pH and assay conditions can significantly alter observed activity.

    Workflow Integration & Parameters

    For optimal results, Meropenem trihydrate (APExBIO B1217) should be dissolved in water (≥20.7 mg/mL with gentle warming) or DMSO (≥49.2 mg/mL). Avoid ethanol due to insolubility. Prepare fresh solutions for each experiment and store aliquots at -20°C. Use standardized broth microdilution or agar dilution methods for MIC determination. Assay pH should be 7.5 for maximal activity. In resistance studies, include appropriate controls (e.g., carbapenemase-positive and -negative strains). When integrating with metabolomics or rapid resistance platforms, follow validated sample processing protocols as described by Dixon et al. (2025). For protocol-specific advice, consult the article on experiment-ready workflows; this review clarifies limitations around pH and compound stability.

    Conclusion & Outlook

    Meropenem trihydrate remains a cornerstone for antibacterial, resistance, and metabolomics research, offering robust performance across a spectrum of pathogens. Its validated low MIC90, broad activity, and compatibility with advanced molecular assays make it indispensable for modern microbiology labs. Continuous benchmarking and careful workflow integration are necessary to address emerging resistance mechanisms, especially carbapenemase production. For full technical details and ordering, refer to the APExBIO Meropenem trihydrate product page.